PosterSessionOnline

EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN..

38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

26-28 October 2022 Amsterdam

N. Poster

Poster title

Applicant name

Status


P-005	Change in AQP4-IgG serostatus in NMOSD: A Laboratory-Based Analysis of Patients with Serial Collections	Amy Kunchok	Received

P-007	Efficacy Comparison of Time to First Adjudicated Attack with Inebilizumab vs Satralizumab in NMOSD: a Matching-Adjusted Indirect Comparison of Monotherapy Registrational Trials	Amy Cohen	Received

P-011	Association of B cell Subsets and Aquaporin-4 antibody titers with Disease Activity in Participants in the N-MOmentum trial Receiving Inebilizumab Treatment	Amy Cohen	Received

P-016	Aquaporin-4 IgG seropositive neuromyelitis optica spectrum disorder and cancer: a data-driven investigation.	Alessandro Dinoto	Received

P-022	Predicting the risk of long-term relapsing disease in MOGAD: Does early relapse predict chronicity?	Anna Francis	Received

P-034	How to translate PASAT scores into SDMT scores for follow-up of cognition in MS	Guy Nagels	Received

P-042	Performance Differences Observed With Fixed Versus Dynamic Reference Keys Within Konectom Smartphone-Based Cognitive Processing Speed Test	Carly Litwiler	Received

P-044	Association of Hormonal Dysregulation with Clinical- and Patient-Reported Outcomes in Pediatric Multiple Sclerosis	Neda Sattarnezhad	Received

P-051	Hidden symptoms drive progression independent of relapse activity in relapsing-onset multiple sclerosis patients	Emilio Portaccio	Received

P-052	Longer-term safety and efficacy of ofatumumab in recently diagnosed and treatment nave patients is consistent with the overall population in the ALITHIOS open-label extension study	Rohit Bhandari	Received

P-053	Progressive Motor Impairment from Critical Demyelinating Lesions of the Cervicomedullary Junction	Caitlin Tarlton	Received

P-054	Clinical characteristics and disability progression in late-onset MS	Elena Flavia Mouresan	Received

P-069	Proportion of Life and Incidence of Multiple Sclerosis in Canadian Immigrants	Dalia Rotstein	Received

P-070	Education and income prior to multiple sclerosis onset strongly affects disease severity	Anna He	Received

P-075	Interferon- or peginterferon-beta 1a exposure during pregnancy in women with multiple sclerosis: outcomes on child development	Kerstin Hellwig	Received

P-076	Pregnancy in women with Multiple Sclerosis: Recommendations from the French Multiple Sclerosis Society	Sandra VUKUSIC	Received

P-087	Association between frailty and free-living walking performance in people with multiple sclerosis: a multicenter cross-sectional study.	Tobia Zanotto	Received

P-093	Longitudinal Association of Intra-Task Measures Derived from a Technology-Enabled 9-Hole Peg Test with Disease Progression and Quality of Life in Multiple Sclerosis	Carly Litwiler	Received

P-100	Screening for cognitive impairment in an uned cohort of patients with MS using BICAMS in outpatient neurology department, Dublin, Ireland	Alexandra Asman	Received

P-106	Capturing qualitative follow up data in a real-world study to assess disease modifying therapy use in the Multiple Sclerosis population before the pandemic and after: An update from the OPTIMISE:MS pharmacovigilance study	Lucia Bianchi	Received

P-110	Uncovering Challenges in Achieving Health Equity in Multiple Sclerosis Care: A Deep-Dive into the Experiences and Perspectives of Patients and Their Care Teams in General Neurology and MS Specialty Clinics	Mitzi Joi Williams	Received

P-111	Evaluation of paramagnetic rim lesions as a marker of disability.	Riccardo Nistri	Received

P-116	Anti- CD20 Agents Are Associated with Higher Incidence and Severity of Breakthrough COVID-19 Infections In Vaccinated People with Multiple Sclerosis - An Observational Study by theNewYorkCOVID-19Neuro-ImmunologyConsortium (NYCNIC)	Sylvia Klineova	Received

P-118	COVID-19 in multiple sclerosis: update from the nation-wide Austrian registry	Gabriel Bsteh	Received

P-119	The coronavirus disease of 2019 is associated with disability worsening in patients with multiple sclerosis	Gertjan Peeters	Received

P-124	Teleneurology as a tool to overcome disparities for access to multiple sclerosis care	Marisa McGinley	Received

P-128	Multimodal bioinformatic analysis of clinical, neuropathology and molecular profiling of progressive MS	Roberta Magliozzi	Received

P-129	Diffusely abnormal white matter and elevated grey matter demyelination imply rapid and severe progression in atypical multiple sclerosis.	Roberta Magliozzi	Received

P-131	Evolutionarily conserved signatures of microglia in health and disease	Victor Salinas	Received

P-141	Limited cross-ancestry portability of European-derived Multiple Sclerosis polygenic risk scores: a study in 50,000 individuals of South Asian ancestry from the Genes & Health cohort	Joshua Breedon	Received

P-153	Brain-specific T cells from multiple sclerosis patients have a T central memory phenotype and express adhesion molecules and chemokine receptors necessary for migration to brain	John William Lindsey	Received

P-155	Quantitative proteomics reveals protein dysregulation during T cell activation in multiple sclerosis patients compared to healthy controls	Tone Berge	Received

P-162	EPSTEIN-BARR VIRUS AND MULTIPLE SCLEROSIS IN A SPANISH COHORT. A TWO-YEARS LONGITUDINAL STUDY	Roberto Alvarez Lafuente	Received

P-164	Short-chain fatty acids (SCFAs): propionate, butyrate, and acetate are associated with clinical, radiological, and immunological parameters in multiple sclerosis patients.	Roberto Alvarez Lafuente	Received

P-174	Evaluating the Effect of a Brutons Tyrosine Kinase Inhibitor in a Murine Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis	Dimitry Ofengeim	Received

P-178	Characterizing the immunomodulation and remyelination efficacy of 20-aHydroxycholesterol in pre-clinical models of multiple sclerosis	Simon Gregory	Received

P-179	Women have higher brain reserve against functional decline in MS than men	Victoria Leavitt	Received

P-194	Toward a joint automated assessment of cortical and paramagnetic rim lesions with 7T MRI	Francesco La Rosa	Received

P-209	Assessing the performance of an automated decision-support system for detecting active T2 lesions on non-standardized MRI systems and field strengths.	Sergi Valverde	Received

P-215	Spinal cord atrophy predicts silent progression in relapse-onset multiple sclerosis	Antje Bischof	Received

P-217	Thalamic node strength connectivity is altered in cognitive impaired MS patients	Antonia Leonie Charlotte Wenger	Received

P-223	Alterations in Nuclei-Specific Thalamic Resting-State Functional Connectivity in Multiple Sclerosis: Implications for Clinical Disability and Cognition	Elsa Salim Karam	Received

P-224	Multiple Sclerosis MRI Reports Vary Among Neuroradiologists	Kelly Leyden	Received

P-227	A Novel Deep Learning Algorithm for Multi-Modal Multiple Sclerosis Lesion Segmentation	Carly Litwiler	Received

P-240	Prognostication of disease activity in multiple sclerosis using retinal layer thickness z-scores	Ting-Yi Lin	Received

P-248	Coagulation activation in relapsing-remitting multiple sclerosis with relapse-associated lymphopenia	Tatiana Koudriavtseva	Received

P-249	A novel signature of lipoxin A4 and prostaglandin E2 in plasma associated with disease severity in patients with relapsing-remitting and secondary progressive multiple sclerosis	Rohit Bhandari	Received

P-251	Investigation of Serum Based Proteomic Biomarker Signatures Relative to Steroid Responsiveness and Disease Activity Status in Relapsing Multiple Sclerosis Patients	Ferhan Qureshi	Received

P-253	Serum neurofilament light chain and glial fibrillary acidic protein are associated with future brain atrophy and T2 lesion volume in progressive multiple sclerosis patients	Taylor Saraceno	Received

P-254	Prognostic value of neurofilament light and glial fibrillary acidic protein for disability worsening PIRA by age range in multiple sclerosis	Taylor Saraceno	Received

P-255	Impact of estimated blood volume and body mass index on glial fibrillary acidic protein and neurofilament light chain measurements in serum and cerebrospinal fluid of multiple sclerosis patients	Yavor Yalachkov	Received

P-258	Differential diagnosis of MS patients versus disease state controls and classification of MS subtypes using serum proteomics	Ferhan Qureshi	Received

P-262	Clinical course of idiopathic acute transverse myelitis in adults with myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and seronegative	Marcell Guimarães	Received

P-263	Cerebrospinal fluid B cell and neuroaxonal damage biomarkers:correlation with relapses and long-term disability in Multiple Sclerosis	Krzysztof Smolik	Received

P-266	CSF and serum biomarkers in human neural stem cell-treated Secondary Progressive Multiple Sclerosis patients.	Giada DAloisio	Received

P-276	Molecular Imaging of Microglia Activation in Patients with Multiple Sclerosis Before and After High Efficacy Treatment with Ocrelizumab	Freja Jespersen	Received

P-279	Early prediction of multiple sclerosis using scanning laser ophthalmoscopy (SLO) video sequence data with a Deep Learning (DL) based approach	Lon Dowell	Received

P-287	Cladribine and Pregnancy in Women with Multiple Sclerosis a Case Series from Germany	Karen Dost-Kovalsky	Received

P-298	Comparative pharmacology of ofatumumab versus ocrelizumab in humanised-CD20 transgenic mice	Rohit Bhandari	Received

P-304	Decision-making factors in patient choice to initiate treatment with cladribine: A preliminary baseline analysis from the STATURE study	Michelle Allan	Received

P-311	Real-world experience with cladribine tablets in an aged /=50 years cohort	Donald Negroski, MD	Received

P-315	Cyclophosphamide in acute treatment of severe neuroinflammatory disorders	Allison Osen	Received

P-319	NVG-291 Phase 1 Results and Phase 2 Study Design in Individuals with Relapsing-remitting Multiple Sclerosis	Daniel Mikol	Received

P-325	Siponimod stabilises physical disability scores in people living with secondary progressive multiple sclerosis after 2 years of treatment: Analysis from the Novartis Global Managed Access Program	Rohit Bhandari	Received

P-327	Serum GFAP and long-term outcomes in high efficacy versus low efficacy early treatment in multiple sclerosis	Taylor Saraceno	Received

P-332	Rituximab in Paediatric Onset Multiple Sclerosis A European Multicenter Experience	Fredrik Sandesj	Received

P-333	Long-term effectiveness of extended interval dosing of natalizumab in multiple sclerosis.	Lana Zhovtis Ryerson	Received

P-335	Natalizumab treatment satisfaction in the TONiC-MS study: preliminary results	Carly Litwiler	Received

P-337	Natalizumab Wearing-off Symptoms: effect of Extend Interval Dosing during Sars-CoV-2 pandemic	Giuseppe Magro	Received

P-345	Humoral Immune Response to COVID-19 mRNA Vaccines in Patients With Relapsing Multiple Sclerosis Treated With Ofatumumab	Erin Moskal	Received

P-346	The Impact of Ocrelizumab on Immunoglobulin Levels and the Risk of Infection.	Kyle Smoot	Received

P-350	Exploratory Magnetic Resonance Imaging Endpoints From NOVA: A Randomized Controlled Study of the Efficacy of 6-Week Dosing of Natalizumab vs Continued 4-Week Treatment for Multiple Sclerosis	Carly Litwiler	Received

P-365	SISTER Subcutaneous: Non-interventional, observational, prospective, German multicentre, open label study over 12-months for Tysabri Patient Preference Experience from Real World Preliminary results of the 1st interim analysis	Ksenija Schirduan	Received

P-368	Utilization, safety, and tolerability of ocrelizumab: Data from the Providence Ocrelizumab Registry	Kyle Smoot	Received

P-372	Proof of Concept for 2-stage Models of Heterogeneous Treatment Effects Derived from the Real-World MS PATHS Research Network	Carly Litwiler	Received

P-373	Long-term effectiveness of natalizumab for RRMS: Dutch and global interim results from TYSABRI Observational Program	Carly Litwiler	Received

P-375	Two years efficacy and safety results from Real World Experience for cladribine tablets in management of relapsing Multiple sclerosis in Qatar	Rupali Bahri	Received

P-383	Autologous hematopoietic stem cell transplantation for MS. The Dutch experience of patients going abroad	Ellen P.A. Kramer	Received

P-384	Treatment Preferences Among Health Care Providers in Selecting Disease Modifying Therapies for Multiple Sclerosis: A Discrete Choice Experiment	Carly Litwiler	Received

P-385	IVIG treatment for acute MOGAD attacks- A retrospective multicenter observational study	Itay Lotan	Received

P-389	Comparing the Risk and Severity of Infusion-Related Reactions in Patients Premedicated with Cetirizine versus Diphenhydramine Prior to Ocrelizumab Infusions (PRECEPT)	Kyle Smoot	Received

P-405	Predictors of early serologic diagnosis of aquaporin-4 IgG positive NMOSD	Dalia Rotstein	Received

P-410	Population-based mortality data of the Danish nationwide AQP4 antibody-seropositive NMOSD cohort	Viktoria Papp	Received

P-411	Inebilizumab reduces attack risk independent of Low Affinity IgG Fc Region Receptor III-A Gene Polymorphisms in Neuromyelitis Optica Spectrum Disorder	Amy Cohen	Received

P-412	Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews	Reece Bracewell	Received

P-415	Spatial association between gene expression and brain damage in neuromyelitis optica spectrum disorders	Laura Cacciaguerra	Received

P-417	Characterisation of Disease Severity and Stability in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews	Reece Bracewell	Received

P-419	Safety and Efficacy of Inebilizumab in AQP4 NMOSD Participants with history of Immunosuppression Treatment prior to N-MOmentum Study	Amy Cohen	Received

P-422	Quantitative MRI measures of MOGAD compared to MS, NMOSD and healthy controls	Amy Kunchok	Received

P-426	A Retrospective Investigation of MOG-IgG Titers in Relapse and Disability Prediction in Adult and Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Patients	Jamie McDonald	Received

P-431	Predictors of suicidal ideation in people with multiple sclerosis.	Benjamin N Cassidy	Received

P-439	The seasonal fluctuation of fatigue in multiple sclerosis	Matthias Grothe	Received

P-445	The efficacy of Natalizumab on inflammatory parameters of disease activity in Pediatric-Onset Multiple Sclerosis patients	Marta Gaggiola	Received

P-446	Progression independent of relapse activity is the main determinant of disability accumulation in relapsing-onset multiple sclerosis patients	Emilio Portaccio	Received

P-447	Determine whether relapse associated worsening can be separated from PIRA using the MSIS-29 PRO in the UKMSR.	Alessia Curcio Rubertini	Received

P-450	The late onset of emotional distress in people with progressive multiple sclerosis during the COVID-19 pandemic: longitudinal findings from the CogEx study	Anthony Fesintein	Received

P-456	Deciphering Multiple Sclerosis disability progression in the elderly: a multicenter cohort study	Jean-Christophe OUALLET	Received

P-458	Self-reported disabilities and health-related quality of life in persons with multiple sclerosis in the Netherlands: 10-year prospective web-based study in a population-based real-life cohort	Peter Joseph Jongen	Received

P-466	Influence of socio-economic status on excess mortality of multiple sclerosis	Sarah Wilson	Received

P-476	Comparison of anti-CD20 therapies versus other disease modifying therapies on postpartum disease activity in patients with multiple sclerosis	Michlene Passeri	Received

P-478	Interferon beta exposure during pregnancy and breastfeeding: Impact on birth outcome and child development Results from the post-authorisation safety study PRIMA	Juliane Klehmet	Received

P-484	SLEEP APNEA AND PERIODIC LIMB MOVEMENTS ARE HIGHLY PREVALENT IN PATIENTS WITH MULTIPLE SCLEROSIS	Miklos Palotai	Received

P-491	Remote Web-Based Assessment of Cognition, Mood and Fatigue in People with Multiple Sclerosis	Emily Thorp	Received

P-492	Learning from pseudo-labels: deep networks improve classical longitudinal brain volume change estimation for patients with MS	Geng Zhan	Received

P-493	Neurostatus-eEDSS results in high consistency of expanded disability status scale assessments: Experience from 13 clinical trials	Laura Khurana	Received

P-499	Motion capture of the manual dexterity test to categorize hand function in multiple sclerosis	Marisa McGinley	Received

P-509	Predicting Expanded Disability Status Scale (EDSS) using Patient Reported Outcomes (PROs)	Lars Forsberg	Received

P-514	Sustained Decrease of Income in Multiple Sclerosis: A new possible disability outcome measure of disease progression.	Athanasia E. Christakou	Received

P-515	Long-term outcome after COVID-19 infection in multiple sclerosis: a matched-controlled study in a nation-wide Austrian registry	Gabriel Bsteh	Received

P-518	Clinical course of multiple sclerosis and patient experiences during breast cancer treatment	Alyssa Nylander	Received

P-521	Views from an international multiple sclerosis patient community on the future of their clinical care.	Robert Sloan	Received

P-522	Remote passive monitoring in people living with progressive multiple sclerosis during the COVID-19 pandemic shows a measurable reduction in daily activity	Maxime Usdin	Received

P-525	Neuronal loss in the thalamus and pons correlates with disease severity: Interim analysis of a large digital pathology study.	Benjamin COOZE	Received

P-531	Accelerated cellular senescence in progressive multiple sclerosis	Dimitrios Papadopoulos	Received

P-535	Pharmacological microglia depletion followed by repopulation ameliorates recurrent cuprizone-induced demyelination	Tiago Medeiros Furquim	Received

P-545	Peripheral blood immune markers associated with immunosenescence in multiple sclerosis and healthy controls	Catherine Larochelle	Received

P-546	Upregulated complement receptors correlate with Fc gamma receptor 3A-positive natural killer cells and natural killer-T cells in neuromyelitis optica spectrum disorder.	Shuhei Nishiyama	Received

P-548	Mucosal associated invariant T (MAIT) cells mediate the crosstalk between the gut and the brain in people with Multiple Sclerosis (MS)	Laura Ghezzi	Received

P-556	GB7208 is a CNS-penetrant BTK inhibitor demonstrating potent activity on pathogenic pathways implicated in Multiple Sclerosis	Daniel Bachteler	Received

P-564	Spike antibody seroconversion and breadth following SARS-CoV-2 vaccination in Australian people with Multiple Sclerosis	Fabienne Brilot	Received

P-568	Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with household chemical exposures	Zahra Nasr	Received

P-569	Smoking and Multiple Sclerosis risk in Blacks: a nested case-control study	Vinicius Schoeps	Received

P-572	Expansion Of Chronic Active Multiple Sclerosis Lesions Is Linked to the Dysregulation of Cholesterol Metabolism	Kristen Hawkins	Received

P-575	Hyaluronan Synthesis and Catabolism as Therapeutic Targets for Cognitive Disturbances in Multiple Sclerosis	Larry Sherman	Received

P-589	MULTIPARAMETRIC QUANTITATIVE MRI FOR BRAIN MICROSTRUCTURAL TISSUE CHARACTERIZATION IN MULTIPLE SCLEROSIS	Henri Trang	Received

P-603	Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis	Samuel Klistorner	Received

P-604	Pattern of Thalamic Nuclei Atrophy in Early Relapse-Onset Multiple Sclerosis	Sarah Levy	Received

P-609	Investigating the relationship between white matter tracts and cognitive impairment in relapsing-remitting multiple sclerosis patients	Mahmoud Elkhooly	Received

P-610	Implementation of standardized MRI finding report form for daily neurological practice in Germany	Birte Elias-Hamp	Received

P-618	Assessment of Candidate MRI Biomarkers of Ongoing MS Disease in the Absence of Acute Inflammation	Carly Litwiler	Received

P-645	OPTICAL COHERENCE TOMOGRAPHY IS ASSOCIATED WITH COGNITIVE AND PHYSICAL DISABILITY INDEPENDENTLY OF OTHER BIOMARKERS	Nuria Cerdá Fuertes	Received

P-648	Cerebrospinal fluid analysis in a paediatric cohort of patients with MOG antibody associated disorders.	Giulia Galati	Received

P-653	Blood Serum Proteome Correlates of Multiple Sclerosis Disease Progression as evaluated by Clinical and Brain Atrophy Outcomes: A 5-Year Longitudinal Study	Ferhan Qureshi	Received

P-654	Clinical Phenotypes from Blood Serum Protein Concentration	Ferhan Qureshi	Received

P-658	Expression of the cell senescence marker p16ink4a is elevated in MS patients and reduced in those on B-cell depleting therapies	Jennifer Graves	Received

P-664	Use of individual measure and Z-scores to monitor disease course in Relapsing Multiple Sclerosis: A 1-year Prospective Study in a Single Center.	Luis Rafael Solís-Tarazona	Received

P-678	Pathophysiological mechanisms of motor fatigue in people with multiple sclerosis: new insights from advanced neurophysiological techniques	Giorgio Leodori	Received

P-681	What if its not MS? Long-term outcomes in other paediatric monophasic and multiphasic demyelinating syndromes	Charly Billaud	Received

P-690	GB7208 is a novel, highly potent and ive CNS-penetrant BTK inhibitor for neuroinflammatory and neurodegenerative diseases	Daniel Bachteler	Received

P-694	The MultipleMS prospective cohort study: Clinical characteristics and treatment of patients with Multiple Sclerosis in seven European countries	Martina Wenzel	Received

P-696	Oral N-acetylglucosamine in Multiple Sclerosis Patients Raises N-glycan branching and Lower Serum Levels of Inflammatory Cytokines	Michael Sy	Received

P-701	Multiple Sclerosis Patient Types, Treatment Patterns, and Therapy Selection Considerations: Patient-Level Retrospective Chart Audit Data Comparison by Managing Physician Specialty	Emma McFadden	Received

P-708	Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis	Carly Litwiler	Received

P-712	Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Final Safety and Efficacy Results from the Phase 3 EVOLVE-MS-1 Study	Carly Litwiler	Received

P-713	Preserved T cell but attenuated antibody response in MS patients on Fingolimod and Ocrelizumab following 2ndand 3rdSARS-CoV-2mRNA vaccine	SHRISHTI SAXENA	Received

P-720	Preservation of Myelin in Patients with Relapsing Multiple Sclerosis Treated with Ponesimod Compared to Teriflunomide	Rabi Panigrahy	Received

P-724	Predictors of hospitalization due to infection in rituximab treated MS-patients	Jakob Rishovd Karlowicz	Received

P-726	COVID-19 outcomes in fingolimod- or siponimod - treated patients: Clinical trial and post marketing cases	Rohit Bhandari	Received

P-733	The Impact of Disease Modifying Therapy on Information Processing Speed in Multiple Sclerosis	Albert Aboseif	Received

P-734	Compliance and Persistence With Ofatumumab Treatment in Patients with Relapsing Multiple Sclerosis in Clinical Trials for Up to 4 Years	Rohit Bhandari	Received

P-735	Flushing and Gastrointestinal Adverse Event Analysis from the Phase 3 EVOLVE-MS-1 Study of Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis	Carly Litwiler	Received

P-738	Long-term safety of teriflunomide in multiple sclerosis patients: results of prospective comparative studies in three European countries	Melinda Magyari	Received

P-743	Multiple sclerosis, rituximab, SARS-CoV-2 vaccination, and COVID-19 severity	Annette Langer-Gould	Received

P-750	StratifyJCVTM serum anti-JCV antibody assay for natalizumab patients: Unilabs global cohort data descriptive analysis and Unilabs customer satisfaction survey results	Carly Litwiler	Received

P-755	Soluble vascular cell adhesion molecule-1 and natalizumab plasma concentration as potential biomarkers for monitoring treatment of multiple sclerosis patients with natalizumab	Michael Auer	Received

P-757	Therapeutic efficacy of MRI: Association between MRI utilization and DMT switch among people with MS in the United States	Hayden Naizer	Received

P-759	Rapid discontinuation of baclofen as a treatment for spasticity among MS patients with incident and prevalent diagnoses	Kelsi Smith	Received

P-760	Botulinum toxin trial treatment for MS- tremor: a randomized, double-blinded study.	Anneke van der Walt	Received

P-766	Early MRI activity predicts subsequent disease activity in multiple sclerosis patients treated with cladribine	Carlos Manuel Romero-Sanchez	Received

P-767	Assessing the Impacts of Persistency for Disease Modifying Therapies in a German Registry for Multiple Sclerosis	Maximilian Schuier	Received

P-773	EXPERIENCE WITH CLADRIBINE IN MULTIPLE SCLEROSIS PATIENTS IN THE THIRD AND FORTH YEAR OF TREATMENT	Virgnia Meca-Lallana	Received

P-778	Polypharmacy, anticholinergic medication burden, and objective cognitive performance in adults with multiple sclerosis (MS)	Joanie Huebner	Received

P-782	Wearing-off effect reports of people with Multiple Sclerosis treated with Ocrelizumab in Canada: A descriptive summary of Real-World Data	Victor Gitman	Received

P-783	Patients experience and quality of care when moving to at home natalizumab: a prospective evaluation of multiple sclerosis patients (TYSAD-35)	Simon Lamy	Received

P-788	A Randomized, Double-blind Controlled Clinical Study to Determine the Effectiveness, Safety and Tolerability of Actoferon Compared to Betaferon in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)	Ali Etemadrezaei	Received

P-795	A pilot study examining the feasibility and acceptability of a weight loss and healthy lifestyle intervention in people with multiple sclerosis	Julia Cozart	Received

P-1181	Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis	Marton Knig	Received

P-1183	Ocrelizumab extended interval dosing compared to standard dosing - a safe alternative with significantly decreased immunoglobulin M deficiency rates	Torge Rempe	Received

P-1185	Combining levels of serum neurofilament light chain with CSF glial fibrillary acidic protein improves the prediction of long-termclinical outcomes in multiple sclerosis	Simon Thebault	Received

P-1186	MRI Characteristics of Critical Spinal Cord Demyelinating Lesions Associated with Progressive Motor Impairment	Mark Keegan	Received

P-1192	ACAPELLA: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Late Breaking Data	Elizabeth Douglas	Received

P-1198	Serum Neurofilament Light Chain Levels and NEDA-3 Status With Ofatumumab Treatment in RMS Patients: Longer-term Analysis from ASCLEPIOS I/II and ALITHIOS	Rohit Bhandari	Received

P-1200	Anti-Argonaut antibodies as a potential biomarker in NMORD	Sara Carta	Received

P-1202	Assessing lesion sensitivity and brain atrophy using portable low-field MRI in multiple sclerosis	Joel Stein	Received

P-1203	Progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis patients on injectable vs oral first line Disease Modifying Therapies: an Italian MS registry study	Aurora Zanghì	Received

P-1204	Amyloid and some tau proteinopathy are observed in a subset of individuals with Multiple Sclerosis	Mariko Taga	Received

P-1205	Vaccination behaviour in people diagnosed with multiple sclerosis	Sonia Darvishi	Received

P-1208	Multiple Sclerosis disease states as identified by unsupervised machine learning on multimodal longitudinal patient trajectories	Rohit Bhandari	Received

P-1209	Anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis treated with natalizumab	Carly Litwiler	Received

P-1210	Efficacy of Early Ofatumumab versus Late-Switch from Teriflunomide: Subgroup Analysis of the ALITHIOS Open-Label Extension Study by Prior Disease Modifying Therapy Exposure and Age	Rohit Bhandari	Received

P-1211	Open-label, Multicentre, Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients With Relapsing Multiple Sclerosis Treated With Ofatumumab: Interim Results	Erin Moskal	Received

38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

26-28 October 2022 Amsterdam

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 26/10/2022 TO 26/10/2022

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access